Search
Showing results for "lung disease preterm"
Maternal immunization with pneumococcal conjugate vaccine (PCV) may protect young infants in high-risk settings against the high risk of pneumococcal infections in early life. The aim of this study was to determine the safety and immunogenicity of 13-valent PCV (PCV13) in healthy women of childbearing age in PNG.
The P3-MumBubVax intervention is feasible and acceptable in the Australian public antenatal setting
RV1 and RV5 were both effective in preventing laboratory confirmed and notified rotavirus infections among children aged <5 years
Streptococcus pneumoniae causes substantial morbidity and mortality among children. The introduction of pneumococcal conjugate vaccines (PCV) has the potential to dramatically reduce disease burden. As with any vaccine, it is important to evaluate PCV impact, to help guide decision-making and resource-allocation.
The majority of midwives supported vaccination, although a spectrum of beliefs and concerns emerged
We outline three scenarios from across the health spectrum where issues with health informatics are exemplified.
This study aimed to identify a CIS peripheral blood signature that may provide clues for potential immunomodulatory approaches early in disease
Functional role of CTGF in altering disease progression in a lymphoid malignancy
Early detection of the cyanobacterium Pseudomonas aeruginosa in the lungs of young children with cystic fibrosis (CF) is considered the key to delaying...
Maternal, umbilical cord, neonatal inflammatory, hematologic markers, histologic chorioamnionitis...